Novartis AG - 26 Year Stock Price History | NVS

Historical daily share price chart and data for Novartis AG since 1996 adjusted for splits. The latest closing stock price for Novartis AG as of June 23, 2022 is 81.86.
  • The all-time high Novartis AG stock closing price was 106.12 on July 20, 2015.
  • The Novartis AG 52-week high stock price is 95.17, which is 16.3% above the current share price.
  • The Novartis AG 52-week low stock price is 79.09, which is 3.4% below the current share price.
  • The average Novartis AG stock price for the last 52 weeks is 86.92.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novartis AG Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 87.2595 87.8700 93.7500 80.1100 81.8600 -6.41%
2021 87.9197 94.3700 98.4700 79.7000 87.4700 -7.37%
2020 87.3781 94.9500 99.0100 70.6700 94.4300 -0.27%
2019 88.6709 84.0600 96.1400 75.4000 94.6900 10.35%
2018 82.7945 84.6800 93.9100 72.4400 85.8100 2.20%
2017 80.5118 72.8300 86.6500 70.0300 83.9600 15.27%
2016 76.7115 85.7500 86.2100 67.5900 72.8400 -15.34%
2015 97.2964 92.2500 106.1200 83.9600 86.0400 -7.14%
2014 88.0541 78.7200 96.6500 78.2000 92.6600 15.28%
2013 73.0721 63.8300 80.3900 63.7000 80.3800 26.98%
2012 57.5083 58.1800 63.9600 51.4800 63.3000 10.72%
2011 57.3696 59.2400 64.5200 51.6500 57.1700 -3.02%
2010 53.0627 52.6100 59.7700 43.7800 58.9500 8.30%
2009 44.6554 49.5400 56.1600 33.9600 54.4300 9.39%
2008 51.5838 54.5700 61.0600 43.8500 49.7600 -8.38%
2007 55.5306 58.1400 59.7000 51.6000 54.3100 -5.45%
2006 56.3869 53.4700 61.2400 51.9000 57.4400 9.45%
2005 49.6493 50.2700 54.7000 45.7500 52.4800 3.84%
2004 45.9760 45.9000 50.6200 41.3000 50.5400 10.13%
2003 39.0565 37.1000 45.8900 32.6000 45.8900 24.94%
2002 39.0227 35.7900 43.8300 34.1000 36.7300 0.63%
2001 38.2865 44.8100 45.0000 32.9800 36.5000 -18.44%
2000 37.0009 36.3750 44.7500 29.9400 44.7500 22.18%
1999 39.3345 51.7500 52.2500 34.9350 36.6250 -25.26%
1998 42.7576 41.1850 50.3750 36.1250 49.0000 20.44%
1997 35.4474 28.5650 42.2500 27.3150 40.6850 41.51%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $181.123B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Eli Lilly (LLY) United States $297.134B 35.06
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27